Belimumab Reduces Autoantibodies, Normalizes Low Complement, and Reduces Select B-Cell Populations in Patients With Systemic Lupus Erythematosus

Lignende værker

• Real life experience on the effect of Belimumab in patients with active systemic lupus
  af: Scheinberg, Morton, et al.
  Udgivet: (2014)
• Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
  af: Furie, Richard, et al.
  Udgivet: (2008)
• A Phase 3, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits BLyS, in Patients With Systemic Lupus Erythematosus
  af: Furie, Richard, et al.
  Udgivet: (2011)
• The discovery and development of belimumab: the anti-BLyS–lupus connection
  af: Stohl, William, et al.
  Udgivet: (2012)
• The Effect of Prolonged Treatment with Belimumab on B cells in Human SLE
  af: Jacobi, Annett M, et al.
  Udgivet: (2010)